|Description||ON123300, a dihydropyrido[2,3-d]pyrimidine derivative, has been found to be an effective multikinase inhibitor that could be probably used against brain tumor and mantle cell lymphomas. It is still under preclinical trials in Colorectal cancer. IC50: 3.8|
|Synonyms||UNII-QJ8RO3296G; QJ8RO3296G; CHEMBL3115681; ON123300; SCHEMBL10050883; BDBM50447512|
|Solubility||10 mM in DMSO|
|Application||ON123300 has been found to be an effective multikinase inhibitor that could be probably used against brain tumor and mantle cell lymphomas.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Icahn School of Medicine at Mount Sinai; Onconova Therapeutics|
WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i...
NU2058 is a potent CDK inhibitor. which has CDK2 IC(50)=17 microM and CDK1 IC(50)=26 microM.
SU 9516 is a potent, selective cdk2 inhibitor (IC50 values are 0.022, 0.04, >10, >10, 18 and >100 μM for cdk2, cdk1, cdk4, PKC, p38, PDGFR and EGFR respectively...
Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activi...
CDK9-IN-2 is a novel cyclin-dependent kinase 9(CDK9) inhibitor.
LEE011 succinate hydrate
LEE011 succinate hydrate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with pot...
LEE011 is an orally bioavailable and highly specific CDK4/6 (cyclin-dependent kinase 4/6) inhibitor. LEE011 in combination with LGX818 (a V600E BRAF specific in...
Aminopurvalanol A is a selective, cell-permeable, reversible and ATP-competitive cyclin-dependent kinase (CDK) inhibitor. It is a 2,6,9-trisubstituted purine an...
Indole-3-carbinol is an inhibitor of cell growth via suppressing incorporation of [3H]thymidine, triggering G1 cell cycle arrest and downregulation of cyclin-de...
CDK-IN-2 is a potent and sepecific CDK inhibitor.
ON123300, a dihydropyrido[2,3-d]pyrimidine derivative, has been found to be an effective multikinase inhibitor that could be probably used against brain tumor a...
The hydrochloride salt form of (R)-DRF053, which is a cdk/CK1 inhibitor and could be used in studies in the cancer treatment with combinations of CDK kinase and...
PD 0332991 hydrochloride
PD 0332991 hydrochloride is a cyclin-dependent kinase (CDK) inhibitor with high affinity for CDK4 and CDK6. It has the potential for breast cancer treatment.
SNS-032, also known as BMS-387032, is a 2-aminothiazole-derived, small-molecule cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. ...
RO-3306 is a CDK1 inhibitor with potential anticancer activity. Treatment of growing AML cells with RO-3306 induced G2/M-phase cell cycle arrest and apoptosis ...
Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Selicicl...
BS 181 dihydrochloride is a selective CDK7 inhibitor (IC50 = 21 nM) displaying >40-fold selectivity for CDK7 over others CDKs. BS 181 promotes cell cycle arrest...
AT 7519 mesylate
AT 7519 mesylate is a small-molecule inhibitor of CDK including CDK 1, 2 , 4, 5, 6, and 9 in vitro and it induces apoptosis in multiple myeloma via GSK-3β activ...
AT-7519 is an orally bioavailable small molecule CDK inhibitor with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependen...
PHA-767491 is a potent, ATP-competitive dual cdc7/cdk9 inhibitor (IC50 values are 10 and 34 nM respectively) that prevents initiation of DNA replication.